iOrganBio, a North Carolina-based innovator in intelligent cell manufacturing, announced today the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin, a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, brings decades of academic and entrepreneurial experience that will help expand iOrganBio’s platform into neurological applications.
Dr. Rubin is Co-Director and Principal Faculty of the Harvard Stem Cell Institute and a Professor in Harvard’s Department of Stem Cell and Regenerative Biology. His pioneering work spans blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His appointment signals iOrganBio’s commitment to addressing the challenges of neurodegenerative disease modeling and therapy development.
iOrganBio’s CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency. The platform enables scalable production for disease modeling, drug discovery, and cell therapy development. At its core is the functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver the accuracy, efficiency, and quality needed to accelerate breakthroughs in regenerative medicine and drug development.
The addition of Dr. Rubin is particularly significant given his track record in translating stem cell research into therapeutic candidates. His expertise in applying induced pluripotent stem cells to model neurological diseases and screen drugs aligns with iOrganBio’s goal of enabling FDA-aligned New Approach Methodologies (NAMs). These methodologies offer alternatives to animal testing by using human-relevant in vitro models, potentially reducing drug development timelines and costs.
“We are thrilled to welcome Dr. Rubin to our Scientific Advisory Board,” said iOrganBio’s leadership in the announcement. “His deep understanding of stem cell biology and neurodegenerative disease will be invaluable as we advance our platform for neurological applications.” Dr. Rubin’s entrepreneurial experience, including co-founding biotech companies, is expected to guide iOrganBio’s strategic direction in cell therapy and organoid manufacturing.
The news underscores the growing intersection of artificial intelligence and stem cell biology. By applying engineering precision to biology, iOrganBio aims to overcome the variability and scalability issues that have hindered the adoption of organoids and cell-based assays in drug discovery. With Dr. Rubin’s guidance, the company hopes to unlock new possibilities for modeling complex neurological disorders and developing effective therapies.
For more information, visit iOrgan.Bio.
